Search
Showing results for "early lung health"
he new super science of bioinformatics has been given a $1.3 million boost with the launch of the The McCusker Charitable Foundation Bioinformatics Centre
NEC Australia has joined forces with The Kids Research Institute Australia to ensure a state-of-the-art ICT system is in place at the new Perth Children’s Hospital.
A global philanthropic organisation has backed an Australian-led bid to develop a Strep A vaccine which could save millions of lives around the world.
A quality of life tool developed by disability researcher Jenny Downs is helping to reveal the difference specific interventions can make to the lives of children and families living with disability.
A The Kids Research Institute Australia research student concerned by the types of injuries he was seeing in emergency departments as a trainee doctor has spearheaded an Australia-first study.
An international research collaboration, including The Kids Research Institute Australia infectious disease specialist Tobias Kollmann, has shown that the antiviral drug Interferon can speed up the recovery of COVID-19 patients.
Here we recognise donors who have made cumulative gifts of $10,000 and above to contribute to children's health research at The Kids Research Institute Australia.
Glioblastoma, a lethal high-grade glioma, has not seen improvements in clinical outcomes in nearly 30 years. Ion channels are increasingly associated with tumorigenesis, and there are hundreds of brain-penetrant drugs that inhibit ion channels, representing an untapped therapeutic resource. The aim of this exploratory drug study was to screen an ion channel drug library against patient-derived glioblastoma cells to identify new treatments for brain cancer.
Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial.
Ion channel activity underlying biological processes that drive high-grade gliomas (HGG) is largely unknown. We aimed to determine the networking of ion channel genes and validate their expression within HGG patient tumors, to identify ion channel-targeting drugs that would inhibit tumor-promoting processes.